Sonic Healthcare investing $17.8M to acquire 19.99% of Microba Life Sciences

LabPulse.com staff writers
Nov 29, 2022
Business Agreement Social

Sonic Healthcare has agreed to invest $17.8 million to acquire a 19.99% stake in Microba Life Sciences, Microba said Monday.

Sonic has agreed to pay $.26 per share, representing a 25% premium to the five-day volume-weighted average price of Microba shares ending Sunday.

The firms have also agreed on initial terms for a strategic partnership to distribute Microba's microbiome testing technology in Australia, Germany, U.K., Switzerland, U.S., New Zealand, and Belgium, with the aim of increasing Microba’s addressable market through distribution of its tests throughout Sonic’s network of primary and specialist healthcare professionals.

Sonic is also looking to acquire options for an additional 5% equity position in Microba for $7.5 million, Microba added.

Latest in Point-of-Care Testing
Blood collection on the Babson Diagnostics hand-warmer.
Babson adds hand-warming to blood testing mini-draws in Texas pharmacies
April 16, 2024
Brain Abstract Social
FDA clears another blood-based TBI POC test
April 1, 2024
Visit our Molecular Diagnostics Community
Sponsored
Visit our Molecular Diagnostics Community
April 5, 2024
Omb Final Rule Laboratory Developed Tests March124
FDA LDT oversight battle: Are we close?
March 6, 2024
Related Stories
2019 04 30 22 11 5866 Bacteria 400
Cancer
ESMO study shows microbiome potential for CRC detection
2019 07 25 21 41 6277 Gastrointestinal Digestive System 400
Product Launch
OraSure launches gut microbiome profiling product
2019 07 25 21 41 6277 Gastrointestinal Digestive System 400
Collaboration
Metabolon, DNA Genotek debut at-home microbiome stool test
Visit our Molecular Diagnostics Community
Sponsor Content
Visit our Molecular Diagnostics Community
More in Point-of-Care Testing
Babson adds hand-warming to blood testing mini-draws in Texas pharmacies
By LabPulse.com staff writers
Austin, TX-based Babson Diagnostics said it has received positive feedback for its hand-warmer, which is used as part of a finger-stick blood sample collection device in retail pharmacies.
April 16, 2024
Blood collection on the Babson Diagnostics hand-warmer.
FDA clears another blood-based TBI POC test
By LabPulse.com staff writers
Abbott furthers its point-of-care (POC) assay for measuring traumatic brain injury biomarkers from whole blood.
April 1, 2024
Brain Abstract Social
Labcorp acquires BioReference Health assets
By LabPulse.com staff writers
Labcorp and Opko Health subsidiary BioReference Health have announced that they have made an agreement for Labcorp to acquire certain of BioReference Health’s assets.
March 28, 2024
Hands Shaking2 Social
FDA LDT oversight battle: Are we close?
By Liz Carey
New directions in laboratory developed test (LDT) regulation appeared closer to final rule-making with the March 1 Office of Management and Budget (OMB) acceptance of the LDT final rule, pending regulatory review: a flurry of final rule-making thoughts.
March 6, 2024
Omb Final Rule Laboratory Developed Tests March124
Quest Diagnostics seeks to get a jump on PFAS testing in communities
By Liz Carey
Researchers often use people’s blood PFAS levels as a proxy for exposure to perfluoroalkyl and polyfluoroalkyl substances, the "forever chemicals" found in certain products and the environment.
February 13, 2024
This U.S. Geological Survey (USGS) map shows the number of PFAS detected in tap water samples from select sites across the nation. The findings are based on a USGS study of samples taken between 2016 and 2021 from private and public supplies at 716 locations. The map does not represent the only locations in the U.S. with PFAS. (Source: USGS, public domain.)
Roche signs $350M deal to buy POC technology from LumiraDx
By LabPulse.com staff writers
Roche has entered into a definitive agreement to purchase point-of care (POC) technologies from LumiraDx for $295 million, with an additional payment of up to $55 million to fund the POC diagnostics platform business until the transaction closes.
January 3, 2024
Hands Shaking Deal Social
Quest Diagnostics launches test panel for novel psychoactive substances
By LabPulse.com staff writers
The new "confirmatory testing service" will use definitive liquid chromatography with advanced tandem mass spectrometry-based testing to establish NPS misuse.
December 19, 2023
Quest Diagnostics Newsroom Media Gallery Photo Social
FDA plans to increase oversight of LDTs garner strong response
By Nick Paul Taylor
Plans to increase U.S. Food and Drug Administration (FDA) oversight of laboratory-developed tests (LDTs) have drawn a strong response from trade groups, individuals, and organizations.
November 17, 2023
Fda Sign Dc Social
Talis Biomedical to lay off 90% of workforce, pursue strategic alternatives
By LabPulse.com staff writers
POC testing company Talis Biomedical has announced that it will lay off 90% of its employees and has begun exploring strategic alternatives.
November 15, 2023
Layoff Woman Belongins
Polygenic risk score tests don’t meet expectations, U.K. study shows
By Matt Limb
Polygenic risk scores “perform poorly in screening and prediction of common disease,” failing to identify nearly 90% of patients who develop disease, according to a U.K. study.
October 26, 2023
Dna Sequencing Genome Social
U.K. researchers recommend routine diabetes screening in EDs
By Matt Limb
Diabetes screening should be introduced for patients attending hospital emergency departments (EDs) to prompt earlier treatment where necessary and reduce major health risks, say researchers.
October 10, 2023
Lab Hb A1c Diabetes Social
U.S. government investing $600M in COVID-19 test manufacturing
By LabPulse.com staff writers
The U.S. Department of Health and Human Services announced that it is investing $600 million in funding into COVID-19 test manufacturing.
September 26, 2023
Dollar Money Coronavirus Mask Social
Page 1 of 41
Next Page